Cancer Research Meeting Calendar Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gicquel, C.
Right arrow Articles by Le Bouc, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gicquel, C.
Right arrow Articles by Le Bouc, Y.
[Cancer Research 61, 6762-6767, September 15, 2001]
© 2001 American Association for Cancer Research

Endocrinology

Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors1

Christine Gicquel2, Xavier Bertagna, Véronique Gaston, Joël Coste, Albert Louvel, Eric Baudin, Jérome Bertherat, Yves Chapuis, Jean-Marc Duclos, Martin Schlumberger, Pierre-François Plouin, Jean-Pierre Luton and Yves Le Bouc

Laboratoire d’Explorations Fonctionnelles Endocriniennes, Hôpital Trousseau, AP-HP, 75012 Paris [C. G., V. G., Y. L. B.]; Service des Maladies Endocriniennes et Métaboliques [X. B., J. B., J-P. L.], Chirurgie Viscérale [Y. C.], Informatique Médicale [J. C.] et Service d’Anatomopathologie [A. L.], Hôpital Cochin, AP-HP, 75014 Paris; Clinique d’Hypertension Artérielle, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris [P-F. P.]; Chirurgie Viscérale, Hôpital Saint-Joseph, 75014 Paris [J-M. D.]; Institut Gustave Roussy, 94800 Villejuif, [E. B., M. S.] and Reseau Comete France

Genetic alterations, such as loss of heterozygosity (LOH) at the 17p13 and 11p15 loci and overexpression of the insulin-like growth factor (IGF)-II gene, are associated with the malignant phenotype in sporadic adrenocortical tumors. A high risk of recurrence after surgery for adrenocortical tumors is predicted in cases with regional invasion or distant metastases. However, patients with localized tumors also have a high risk of recurrence. Reliable prognostic markers are required to identify subjects at high risk of recurrence. The aim of this study was to assess the prognostic value of three molecular markers (17p13 LOH, 11p15 LOH, and overexpression of the IGF-II gene) by assessing disease-free survival in a large series of adult patients with sporadic adrenocortical tumors.

Adult patients (114) were prospectively followed up from diagnosis of the disease to June 1999 or to death. Malignancy was initially diagnosed in 18 patients (McFarlane stage III: n = 1 and stage IV: n = 17). The remaining 96 patients with localized adrenal disease at diagnosis (stage I: n = 60 and stage II: n = 36) were at risk of recurrence. Histological grade was assessed according to Weiss criteria, and tumors were classified into two groups (Weiss score <=3 and Weiss score >=4). Tumor samples were analyzed for LOH at the 17p13 and 11p15 loci and for IGF-II gene mRNA content.

17p13 LOH was a strong predictor of shorter disease-free survival in univariate analysis (P = 0.001; relative risk, 27), as were histological grade (Weiss score >=4; P = 0.00001; relative risk, 15), 11p15 LOH (P = 0.004; relative risk, 9), tumor size (size >5 cm; P = 0.006; relative risk, 18), and overexpression of the IGF-II gene (P = 0.01; relative risk, 5). In a Cox proportional hazards regression model, histological grade (P = 0.04; relative risk, 4.2) and 17p13 LOH (P = 0.009; relative risk, 21.5) were independently associated with recurrence.

Molecular markers, particularly 17p13 LOH, are predictive of long-term outcome in patients with sporadic adrenocortical tumors. In patients who have undergone curative surgery, routine assessment of these tumor markers is a useful complement to histological scoring for predicting recurrence and guiding decisions for subsequent follow-up and management.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
L. Groussin, G. Bonardel, S. Silvera, F. Tissier, J. Coste, G. Abiven, R. Libe, M. Bienvenu, J.-L. Alberini, S. Salenave, et al.
18F-Fluorodeoxyglucose Positron Emission Tomography for the Diagnosis of Adrenocortical Tumors: A Prospective Study in 77 Operated Patients
J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1713 - 1722.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. de Reynies, G. Assie, D. S. Rickman, F. Tissier, L. Groussin, F. Rene-Corail, B. Dousset, X. Bertagna, E. Clauser, and J. Bertherat
Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival
J. Clin. Oncol., March 1, 2009; 27(7): 1108 - 1115.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
M. Bielinska, H. Parviainen, S. Kiiveri, M. Heikinheimo, and D. B. Wilson
REVIEW PAPER: Origin and Molecular Pathology of Adrenocortical Neoplasms
Vet. Pathol., March 1, 2009; 46(2): 194 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
C. Rodriguez-Galindo, G. Zambetti, and R. C. Ribeiro
Epidemiology, Clinical Characteristics, and Treatment of Childhood Adrenocortical Tumors
ASCO Educational Book, January 1, 2009; 2009(1): 625 - 629.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C. B d'Alva, G. Abiven-Lepage, V. Viallon, L. Groussin, M. A. Dugue, X. Bertagna, and J. Bertherat
Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess
Eur. J. Endocrinol., November 1, 2008; 159(5): 641 - 647.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. Rizk-Rabin, G. Assie, F. Rene-Corail, K. Perlemoine, H. Hamzaoui, F. Tissier, M. Lieberherr, X. Bertagna, J. Bertherat, and Z. Bouizar
Differential Expression of Parathyroid Hormone-Related Protein in Adrenocortical Tumors: Autocrine/Paracrine Effects on the Growth and Signaling Pathways in H295R Cells
Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2275 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al.
Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
M Volante, C Buttigliero, E Greco, A Berruti, and M Papotti
Pathological and molecular features of adrenocortical carcinoma: an update
J. Clin. Pathol., July 1, 2008; 61(7): 787 - 793.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Libe, A. Fratticci, J. Coste, F. Tissier, A. Horvath, B. Ragazzon, F. Rene-Corail, L. Groussin, X. Bertagna, M. L. Raffin-Sanson, et al.
Phosphodiesterase 11A (PDE11A) and Genetic Predisposition to Adrenocortical Tumors
Clin. Cancer Res., June 15, 2008; 14(12): 4016 - 4024.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P. de Cremoux, D. Rosenberg, J. Goussard, C. Bremont-Weil, F. Tissier, C. Tran-Perennou, L. Groussin, X. Bertagna, J. Bertherat, and M.-L. Raffin-Sanson
Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease
Endocr. Relat. Cancer, June 1, 2008; 15(2): 465 - 474.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu
Molecular Markers and the Pathogenesis of Adrenocortical Cancer
Oncologist, May 1, 2008; 13(5): 548 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. A. Stephan, T.-H. Chung, C. S. Grant, S. Kim, D. D. Von Hoff, J. M. Trent, and M. J. Demeure
Adrenocortical carcinoma survival rates correlated to genomic copy number variants
Mol. Cancer Ther., February 1, 2008; 7(2): 425 - 431.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P. A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, et al.
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
N. Engl. J. Med., June 7, 2007; 356(23): 2372 - 2380.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. Libe, A. Fratticci, and J. Bertherat
Adrenocortical cancer: pathophysiology and clinical management
Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt
The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights
Endocr. Rev., February 1, 2007; 28(1): 20 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Libe, L. Groussin, F. Tissier, C. Elie, F. Rene-Corail, A. Fratticci, E. Jullian, P. Beck-Peccoz, X. Bertagna, C. Gicquel, et al.
Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity
Clin. Cancer Res., February 1, 2007; 13(3): 844 - 850.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Assie, G. Antoni, F. Tissier, B. Caillou, G. Abiven, C. Gicquel, S. Leboulleux, J.-P. Travagli, C. Dromain, X. Bertagna, et al.
Prognostic Parameters of Metastatic Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 148 - 154.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Abiven, J. Coste, L. Groussin, P. Anract, F. Tissier, P. Legmann, B. Dousset, X. Bertagna, and J. Bertherat
Clinical and Biological Features in the Prognosis of Adrenocortical Cancer: Poor Outcome of Cortisol-Secreting Tumors in a Series of 202 Consecutive Patients
J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2650 - 2655.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. S. Kirschner
Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 14 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
L Barzon, G Masi, K Fincati, M Pacenti, V Pezzi, G Altavilla, F Fallo, and G Palu
Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma
Eur. J. Endocrinol., November 1, 2005; 153(5): 629 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
R. Libe and J. Bertherat
Molecular genetics of adrenocortical tumours, from familial to sporadic diseases
Eur. J. Endocrinol., October 1, 2005; 153(4): 477 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R Nawar and D Aron
Adrenal incidentalomas -- a continuing management dilemma
Endocr. Relat. Cancer, September 1, 2005; 12(3): 585 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Tissier, C. Cavard, L. Groussin, K. Perlemoine, G. Fumey, A.-M. Hagnere, F. Rene-Corail, E. Jullian, C. Gicquel, X. Bertagna, et al.
Mutations of {beta}-Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors
Cancer Res., September 1, 2005; 65(17): 7622 - 7627.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Fassnacht, D. Weismann, S. Ebert, P. Adam, M. Zink, F. Beuschlein, S. Hahner, and B. Allolio
AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4366 - 4370.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Betz, I. Shapiro, M. Fassnacht, S. Hahner, M. Reincke, F. Beuschlein, and for the German Austrian Adrenal Network
Peroxisome Proliferator-Activated Receptor-{gamma} Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation
J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3886 - 3896.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. M Pinto, A. E. C. Billerbeck, M. C. B. V. Fragoso, B. B. Mendonca, and A. C. Latronico
Deletion Mapping of Chromosome 17 in Benign and Malignant Adrenocortical Tumors Associated with the Arg337His Mutation of the p53 Tumor Suppressor Protein
J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2976 - 2981.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C D E Margetts, D Astuti, D C Gentle, W N Cooper, A Cascon, D Catchpoole, M Robledo, H P H Neumann, F Latif, and E R Maher
Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas
Endocr. Relat. Cancer, March 1, 2005; 12(1): 161 - 172.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. de Fraipont, M. El Atifi, N. Cherradi, G. Le Moigne, G. Defaye, R. Houlgatte, J. Bertherat, X. Bertagna, P.-F. Plouin, E. Baudin, et al.
Gene Expression Profiling of Human Adrenocortical Tumors Using Complementary Deoxyribonucleic Acid Microarrays Identifies Several Candidate Genes as Markers of Malignancy
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1819 - 1829.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A.-M. Lefrancois-Martinez, J. Bertherat, P. Val, C. Tournaire, N. Gallo-Payet, D. Hyndman, G. Veyssiere, X. Bertagna, C. Jean, and A. Martinez
Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3010 - 3019.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein
The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management
Endocr. Rev., April 1, 2004; 25(2): 309 - 340.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Bertherat, L. Groussin, F. Sandrini, L. Matyakhina, T. Bei, S. Stergiopoulos, T. Papageorgiou, I. Bourdeau, L. S. Kirschner, C. Vincent-Dejean, et al.
Molecular and Functional Analysis of PRKAR1A and its Locus (17q22-24) in Sporadic Adrenocortical Tumors: 17q Losses, Somatic Mutations, and Protein Kinase A Expression and Activity
Cancer Res., September 1, 2003; 63(17): 5308 - 5319.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. Rosenberg, L. Groussin, E. Jullian, K. Perlemoine, S. Medjane, A. Louvel, X. Bertagna, and J. Bertherat
Transcription Factor 3',5'-Cyclic Adenosine 5'-Monophosphate-Responsive Element-Binding Protein (CREB) Is Decreased during Human Adrenal Cortex Tumorigenesis and Fetal Development
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3958 - 3965.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M.-H. Bernard, S. Sidhu, N. Berger, J.-L. Peix, D. J. Marsh, B. G. Robinson, V. Gaston, Y. Le Bouc, and C. Gicquel
A Case Report in Favor of a Multistep Adrenocortical Tumorigenesis
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 998 - 1001.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. J. Giordano, D. G. Thomas, R. Kuick, M. Lizyness, D. E. Misek, A. L. Smith, D. Sanders, R. T. Aljundi, P. G. Gauger, N. W. Thompson, et al.
Distinct Transcriptional Profiles of Adrenocortical Tumors Uncovered by DNA Microarray Analysis
Am. J. Pathol., February 1, 2003; 162(2): 521 - 531.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. A. Koch, K. Pacak, and G. P. Chrousos
The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5367 - 5384.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. Groussin, E. Jullian, K. Perlemoine, A. Louvel, B. Leheup, J. P. Luton, X. Bertagna, and J. Bertherat
Mutations of the PRKAR1A Gene in Cushing's Syndrome due to Sporadic Primary Pigmented Nodular Adrenocortical Disease
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4324 - 4329.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Sidhu, D. J. Marsh, G. Theodosopoulos, J. Philips, C. P. Bambach, P. Campbell, C. J. Magarey, C. F. J. Russell, K.-M. Schulte, H.-D. Roher, et al.
Comparative Genomic Hybridization Analysis of Adrenocortical Tumors
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3467 - 3474.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.